Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Seed amplification assay for the detection of pathologic alpha-synuclein aggregates in cerebrospinal fluid
Luis Concha‐Marambio, Sandra Pritzkow, Mohammad Shahnawaz, et al.
Nature Protocols (2023) Vol. 18, Iss. 4, pp. 1179-1196
Open Access | Times Cited: 121

Showing 1-25 of 121 citing articles:

Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study
Andrew Siderowf, Luis Concha‐Marambio, David-Erick Lafontant, et al.
The Lancet Neurology (2023) Vol. 22, Iss. 5, pp. 407-417
Open Access | Times Cited: 379
A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research
Tanya Simuni, Lana M. Chahine, Kathleen L. Poston, et al.
The Lancet Neurology (2024) Vol. 23, Iss. 2, pp. 178-190
Closed Access | Times Cited: 251
A biological classification of Parkinson's disease: the SynNeurGe research diagnostic criteria
Günter U. Höglinger, Charles H. Adler, Daniela Berg, et al.
The Lancet Neurology (2024) Vol. 23, Iss. 2, pp. 191-204
Closed Access | Times Cited: 239
Depletion of dopamine in Parkinson's disease and relevant therapeutic options: A review of the literature
S Ramesh, Arosh S. Perera Molligoda Arachchige
AIMS neuroscience (2023) Vol. 10, Iss. 3, pp. 200-231
Open Access | Times Cited: 82
Investigating alpha‐synuclein co‐pathology in Alzheimer's disease by means of cerebrospinal fluid alpha‐synuclein seed amplification assay
G. Bellomo, Andrea Toja, Federico Paolini Paoletti, et al.
Alzheimer s & Dementia (2024) Vol. 20, Iss. 4, pp. 2444-2452
Open Access | Times Cited: 35
A cross‐sectional study of α‐synuclein seed amplification assay in Alzheimer's disease neuroimaging initiative: Prevalence and associations with Alzheimer's disease biomarkers and cognitive function
Duygu Tosun, Zachary Hausle, Hirotaka Iwaki, et al.
Alzheimer s & Dementia (2024) Vol. 20, Iss. 8, pp. 5114-5131
Open Access | Times Cited: 20
The Common Alzheimer's Disease Research Ontology (CADRO) for biomarker categorization
Amanda M. Leisgang Osse, Jefferson W. Kinney, Jeffrey L. Cummings
Alzheimer s & Dementia Translational Research & Clinical Interventions (2025) Vol. 11, Iss. 1
Open Access | Times Cited: 2
Biomarker-guided decision making in clinical drug development for neurodegenerative disorders
Jeffrey L. Cummings, Charlotte E. Teunissen, Brian Fiske, et al.
Nature Reviews Drug Discovery (2025)
Closed Access | Times Cited: 2
Combining skin and olfactory α-synuclein seed amplification assays (SAA)—towards biomarker-driven phenotyping in synucleinopathies
Anastasia Kuzkina, Jonas Rößle, A. Seger, et al.
npj Parkinson s Disease (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 35
Cerebrospinal fluid lipoproteins inhibit α-synuclein aggregation by interacting with oligomeric species in seed amplification assays
G. Bellomo, Silvia Paciotti, Luis Concha‐Marambio, et al.
Molecular Neurodegeneration (2023) Vol. 18, Iss. 1
Open Access | Times Cited: 28
Alpha-Synuclein Contribution to Neuronal and Glial Damage in Parkinson’s Disease
Kamil Saramowicz, Natalia Siwecka, Grzegorz Galita, et al.
International Journal of Molecular Sciences (2023) Vol. 25, Iss. 1, pp. 360-360
Open Access | Times Cited: 23
Controlled Supramolecular Polymerization via Bioinspired, Liquid–Liquid Phase Separation of Monomers
Satyajit Patra, Sushmitha Chandrabhas, Shikha Dhiman, et al.
Journal of the American Chemical Society (2024) Vol. 146, Iss. 18, pp. 12577-12586
Closed Access | Times Cited: 15
Clinicopathological correlation of cerebrospinal fluid alpha‐synuclein seed amplification assay in a behavioral neurology autopsy cohort
Niyatee Samudra, D. Luke Fischer, Steven Lenio, et al.
Alzheimer s & Dementia (2024) Vol. 20, Iss. 5, pp. 3334-3341
Open Access | Times Cited: 13
α-Synuclein seed amplification technology for Parkinson’s disease and related synucleinopathies
Claudio Soto
Trends in biotechnology (2024) Vol. 42, Iss. 7, pp. 829-841
Closed Access | Times Cited: 10
Sensitivity and specificity of a seed amplification assay for diagnosis of multiple system atrophy: a multicentre cohort study
Yihua Ma, Carly M. Farris, Sandrina Weber, et al.
The Lancet Neurology (2024) Vol. 23, Iss. 12, pp. 1225-1237
Closed Access | Times Cited: 10
Toward the quantification of α-synuclein aggregates with digital seed amplification assays
Tal Gilboa, Zoe Swank, Rohan A. Thakur, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 3
Open Access | Times Cited: 9
Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial
Pepijn Eijsvogel, Pinaki Misra, Luis Concha‐Marambio, et al.
Nature Medicine (2024) Vol. 30, Iss. 9, pp. 2631-2640
Open Access | Times Cited: 9
Toward a biological definition of neuronal and glial synucleinopathies
Claudio Soto, Brit Mollenhauer, Oskar Hansson, et al.
Nature Medicine (2025)
Closed Access | Times Cited: 1
Evidence for alpha-synuclein aggregation in older individuals with hyposmia: a cross-sectional study
Kenneth Marek, David Russell, Luis Concha‐Marambio, et al.
EBioMedicine (2025) Vol. 112, pp. 105567-105567
Open Access | Times Cited: 1
α-Synuclein Seed Amplification Assay Amplification Parameters and the Risk of Progression in Prodromal Parkinson Disease
David G. Coughlin, Ben Shifflett, Carly M. Farris, et al.
Neurology (2025) Vol. 104, Iss. 5
Closed Access | Times Cited: 1
Early detection of Parkinson’s disease through multiplex blood and urine biomarkers prior to clinical diagnosis
Shuo Gao, Zheng Wang, Yuanfeng Huang, et al.
npj Parkinson s Disease (2025) Vol. 11, Iss. 1
Open Access | Times Cited: 1
Alpha synuclein co-pathology is associated with accelerated amyloid-driven tau accumulation in Alzheimer’s disease
Nicolai Franzmeier, Sebastian Niclas Roemer, Alexander Bernhardt, et al.
Molecular Neurodegeneration (2025) Vol. 20, Iss. 1
Open Access | Times Cited: 1
Gut mucosal cells transfer α-synuclein to the vagus nerve
Rashmi Chandra, Arpine Sokratian, Katherine Ramos Chavez, et al.
JCI Insight (2023) Vol. 8, Iss. 23
Open Access | Times Cited: 22
Fluid and Biopsy Based Biomarkers in Parkinson's Disease
David G. Coughlin, David J. Irwin
Neurotherapeutics (2023) Vol. 20, Iss. 4, pp. 932-954
Open Access | Times Cited: 21
Comparison of biospecimens for α‐synuclein seed amplification assays in Parkinson's disease: A systematic review and network meta‐analysis
Yuanchu Zheng, Siming Li, Yang Chen, et al.
European Journal of Neurology (2023) Vol. 30, Iss. 12, pp. 3949-3967
Closed Access | Times Cited: 20
Page 1 - Next Page

Scroll to top